The Cost Effectiveness of Human Papillomavirus Vaccines
- 1 March 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 72 (5), 715-743
- https://doi.org/10.2165/11599470-000000000-00000
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Impact of vaccinating boys and men against HPV in the United StatesVaccine, 2010
- The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South AfricaVaccine, 2009
- Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in MexicoArchives of Medical Research, 2009
- Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic modelVaccine, 2008
- A Multi-Type HPV Transmission ModelBulletin of Mathematical Biology, 2008
- Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in IndiaBritish Journal of Cancer, 2008
- The economic burden of noncervical human papillomavirus disease in the United StatesAmerican Journal of Obstetrics and Gynecology, 2008
- Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis updateInternational Journal of Cancer, 2007
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006